A Study to Evaluate Satisfaction With Care in Patients With Cancer Receiving Immunotherapy Treatment at Home
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
49actual
Sites
3
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-29 | actual | When the study began enrolling |
| Primary completion | 2025-06-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-12 | actual | The whole study's end, after follow-up |
| First posted | 2023-12-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cancer
- Solid Tumors
Intervention
- Drug: Immunotherapy
Primary outcome
what the primary-completion date above is the date OFChange in patient satisfaction on the European Organisation for Research and Treatment of Cancer satisfaction with cancer care core questionnaire (EORTC PATSAT-C33) when transitioning from Outpatient Hospital to Hospital at Home to receive immunotherapy
measured Participants follow up approximately 24 weeks after transition to treatment at home
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed